Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Exclusion Criteria

• •Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
• •Patients with documented c-KIT mutations.
• •Patients who are receiving any other investigational agents.
• •Patients with known active brain metastases should be excluded. Patients with treated brain metastases with documented stability for 4 weeks are eligible.
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or any of the components of the vaccine being administered as part of this study.
• •Women who are pregnant or nursing/breastfeeding.
• •History of significant bleeding disorder unrelated to cancer, including:
• •* Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
• •* Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
• •Patients currently taking medications that inhibit platelet function (i.e., aspirin, dipyridamole, epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, and any non-steroidal anti-inflammatory drug) because of a potential increased risk of bleeding from dasatinib.
• •Patients currently taking anticoagulants (warfarin, heparin/low molecular weight heparin \[e.g., danaparoid, dalteparin, tinzaparin, enoxaparin\]) because of a potential increased risk of bleeding from dasatinib.
• •Diagnosis of unstable angina or myocardial infarction within 6 months of study entry.
• •Patients currently taking one or more of the following drugs that are generally accepted to have a risk of causing Torsades de Pointes:
• •* quinidine, procainamide, disopyramide
• •* amiodarone, sotalol, ibutilide, dofetilide
• •* erythromycins, clarithromycin
• •* chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
• •* cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
• •Diagnosed or suspected congenital long QT syndrome.
• •Prolonged QTc interval on pre-entry electrocardiogram (\> 450 msec) within 30 days prior to study registration.
• •Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with dasatinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.